Sabine Cerny-Reiterer
Overview
Explore the profile of Sabine Cerny-Reiterer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
2159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, et al.
Neoplasia
. 2018 May;
20(6):632-642.
PMID: 29772458
Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about...
2.
Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr W, et al.
Oncotarget
. 2017 Oct;
8(40):67709-67722.
PMID: 28978065
Acute lymphoblastic leukemia (ALL) is characterized by leukemic expansion of lymphoid blasts in hematopoietic tissues. Despite improved therapy only a subset of patients can be cured. Therefore, current research is...
3.
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, et al.
J Clin Invest
. 2017 May;
127(6):2392-2406.
PMID: 28481221
Quiescent and proliferating leukemia cells accumulate highly lethal DNA double-strand breaks that are repaired by 2 major mechanisms: BRCA-dependent homologous recombination and DNA-dependent protein kinase-mediated (DNA-PK-mediated) nonhomologous end-joining, whereas DNA...
4.
Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, et al.
Vet Comp Oncol
. 2017 Apr;
16(1):55-68.
PMID: 28397975
Background: Mastocytoma are frequently diagnosed cutaneous neoplasms in dogs. In non-resectable mastocytoma patients, novel targeted drugs are often applied. The transcription factor STAT5 has been implicated in the survival of...
5.
Fureder W, Cerny-Reiterer S, Sperr W, Mullauer L, Jager E, Schwarzinger I, et al.
Wien Klin Wochenschr
. 2016 Oct;
129(11-12):404-410.
PMID: 27743175
Patients with aplastic anemia or hypoplastic myelodysplastic syndrome (MDS) may respond to immunosuppressive therapy, including the anti-CD52 antibody alemtuzumab. We analyzed treatment responses to alemtuzumab in 5 patients with MDS...
6.
Cuapio A, Post M, Cerny-Reiterer S, Gleixner K, Stefanzl G, Basilio J, et al.
Oncotarget
. 2016 Jun;
7(29):46466-46481.
PMID: 27341131
Histamine dihydrochloride (HDC) plus IL-2 has been proposed as a novel maintenance-immunotherapy in acute myeloid leukemia (AML). We analyzed the immunophenotype and function of natural killer (NK) cells in blood...
7.
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, et al.
Blood
. 2016 Feb;
127(17):2131-43.
PMID: 26864341
Leukemias expressing constitutively activated mutants of ABL1 tyrosine kinase (BCR-ABL1, TEL-ABL1, NUP214-ABL1) usually contain at least 1 normal ABL1 allele. Because oncogenic and normal ABL1 kinases may exert opposite effects...
8.
Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, et al.
Clin Cancer Res
. 2015 Nov;
22(8):2051-61.
PMID: 26607600
Purpose: In chronic myelogenous leukemia (CML), leukemic stem cells (LSC) represent a critical target of therapy. However, little is known about markers and targets expressed by LSCs. The aim of...
9.
Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, et al.
Blood
. 2015 Oct;
126(26):2832-41.
PMID: 26486787
The Ki-1 antigen (CD30) is an established therapeutic target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma. We have recently shown that CD30 is expressed abundantly in the cytoplasm...
10.
Rathert P, Roth M, Neumann T, Muerdter F, Roe J, Muhar M, et al.
Nature
. 2015 Sep;
525(7570):543-547.
PMID: 26367798
Following the discovery of BRD4 as a non-oncogene addiction target in acute myeloid leukaemia (AML), bromodomain and extra terminal protein (BET) inhibitors are being explored as a promising therapeutic avenue...